Pharmaceutical Supply Chain Governance, Environmental Risk Management, And Sustainable Access to Essential Medicines in Emerging Economies: The PSCG-ERM Framework

for domain-specific supply chain risk threshold calibration (Obogo, Arumosoye, and Obriki, 2020c). Conceptual safety governance model for large commercial facility operations confirms that integrated monitoring of multiple supply chain performance signals achieves better governance outcomes than single-domain approaches (Obogo, Obriki, and Arumosoye, 2022). Advances in workforce safety training models confirms that supply chain governance capacity development requires human capital investment alongside technical infrastructure (Obriki, Obogo, and Arumosoye, 2022). The supply chain risk management model for EPC projects, supply chain resilience framework for critical infrastructure, materials readiness model, regulatory-compliant procurement framework, inventory availability model, strategic procurement optimization framework, cost reduction through vendor governance, and demurrage elimination model collectively confirm that SCSG dimension requirements are validated across multiple industrial supply chain governance contexts (Agbabiaka et al., 2019; Ogunwole et al., 2021; Okonkwo et al., 2021a; Okonkwo et al., 2021b; Okonkwo, Ogunwole, and Okeke, 2018a; Okonkwo, Ogunwole, and Okeke, 2018b; Okonkwo et al., 2019; Okonkwo et al., 2020). Asset lifecycle management and inventory visibility framework confirms the integrated data architecture required for higher maturity SCSG governance (Okonkwo et al., 2023). Supplier relationship management strategies fostering innovation, collaboration, and resilience in global supply chain ecosystems provide direct evidence for the PSCG-ERM's SCSG dimension specification: effective pharmaceutical supply chain governance requires structured vendor engagement programs extending compliance monitoring beyond single-tier supplier relationships, with documented associations between supplier relationship governance maturity and supply continuity outcomes (Ike et al., 2021). End- to-end visibility frameworks improving transparency, compliance, and traceability across complex global supply chain operations confirm that real-time supply chain visibility infrastructure is prerequisite for Level 3 and above SCSG maturity, enabling proactive supply disruption detection rather than reactive shortage management (Nnabueze et al., 2021). Predictive analytics models IJHPR enhancing supply chain demand forecasting accuracy confirm that AI-assisted demand monitoring achieves substantially higher accuracy than historical consumption-based forecasting in complex health system procurement, directly supporting the PSCG-ERM's SCSG dimension Level 4 demand forecasting specification (Aifuwa et al., 2020). Real-time risk assessment dashboards using machine learning in hospital supply chain management systems confirm that integrated ML- based supply chain dashboards are operationally deployable at health system governance levels where shortage response decisions are made, providing the technical reference for SCSG Level 4 quantitative performance monitoring (Filani, Nnabueze, Ike, and Wedraogo, 2022). Lean supply chain practices improving operational efficiency, reducing waste, and enhancing organizational competitiveness confirm that pharmaceutical supply chain performance governance requires waste elimination alongside shortage prevention as complementary SCSG objectives (Ike et al., 2022). Supplier relationship management framework for achieving strategic procurement objectives confirms that vendor governance in pharmaceutical supply chains requires structured qualification and performance measurement systems operating continuously (Akinleye and Adeyoyin, 2022). Conceptual framework for sustainable procurement practices in local manufacturing enterprises in Africa confirms that sustainable procurement governance in emerging economy pharmaceutical supply chains requires differentiated approaches addressing local manufacturing sector capacity constraints (Efobi, Akinleye, and Fasawe, 2022). Conceptual framework for developing a resilience index for post-pandemic supply chains confirms that pharmaceutical supply chain resilience governance requires systematic multi-dimensional resilience indicators addressing disruption anticipation, absorption, adaptation, and recovery capacities directly relevant to SCSG Level 4 and 5 specifications (Efobi, Akinleye, and Fasawe, 2023). Category spend mapping and supplier risk assessment framework for global supply chains confirms that supplier risk governance in complex pharmaceutical supply chains requires structured category-level risk assessment extending beyond single-tier supplier qualification (Akinleye and Adeyoyin, 2023). Integrating AI with ESG metrics in smart infrastructure auditing confirms that AI-assisted environmental compliance monitoring achieves higher auditing accuracy and broader coverage than conventional inspection-based approaches, providing the technical reference for the PSCG- ERM's ERM dimension Level 4 AI-assisted environmental monitoring specification (Okojie et al., 2023a). Predictive analytics models for monitoring smart city emissions and infrastructure risk confirm that emissions monitoring and predictive environmental risk governance represent technically mature capabilities directly informing the PSCG-ERM's ERM environmental standards specification for pharmaceutical manufacturing site air emission monitoring (Okojie et al., 2023b). Automated ESG reporting in energy projects using blockchain-driven smart compliance management systems confirms that blockchain-based compliance documentation provides immutable audit trails for environmental regulatory reporting, supporting the PSCG-ERM's ERM dimension specification for Level 4 automated environmental compliance documentation (Abioye et al., 2023). GIS-enhanced environmental risk assessment model for high-priority industrial redevelopment sites confirms that spatial environmental risk analysis is a mature technical capability applicable to pharmaceutical manufacturing facility site selection and environmental compliance planning (Olamide and Badmus, 2020). Integrated treatment optimization model for remediating multi-media contaminated gas plant environments confirms that pharmaceutical manufacturing site environmental remediation governance requires multi-domain technical expertise spanning chemical, biological, and regulatory compliance dimensions (Olamide and Badmus, 2021). Advanced hydrological modeling for climate-induced watershed vulnerability IJHPR assessment confirms that climate vulnerability assessment for pharmaceutical supply chain water use governance requires specialized environmental risk modeling capabilities (Badmus and Olamide, 2019). A review of health risk assessment and exposure control models for hazardous waste management operations in Africa confirms that pharmaceutical waste management governance in African emerging economy contexts requires health risk assessment frameworks calibrated to local exposure pathway and population vulnerability conditions (Ozobu et al., 2025, cited for cross-domain reference as the environmental risk assessment methodology is applicable to pharmaceutical waste ERM governance assessment). Advances in data-driven investment governance improving sustainability compliance and performance outcomes confirm that sustainability governance investment generates measurable compliance performance improvement when anchored to quantitative performance monitoring systems at the ESG reporting interface (Morah et al., 2022). Public health governance models using process optimization and performance metrics for regulatory oversight confirm that the PSCG-ERM's RCG dimension should encompass public health surveillance capacity as a regulatory governance dimension alongside quality assurance and pharmacovigilance technical functions (Anioke and Atima, 2023a). Public health informatics frameworks for protecting vulnerable populations through data-driven policy enforcement confirm that data-driven regulatory governance in the PSCG-ERM's RCG dimension generates measurable population health protection outcomes enabling equity-adjusted compliance performance assessment (Anioke and Atima, 2023b). Business intelligence applications for mental health resource allocation and public health program accountability confirm that BI governance frameworks are deployable at African health system governance levels relevant to PSCG-ERM DGIM dimension supply chain analytics governance (Anioke and Atima, 2023c). Blockchain- based architectures for tamper-proof regulatory recordkeeping confirm that distributed ledger infrastructure supports immutable regulatory compliance documentation at PSCG-ERM RCG and DGIM Level 4 and Level 5 (Anichukwueze, Osuji, and Oguntegbe, 2021). Framework for aligning organizational risk culture with cybersecurity governance objectives confirms that pharmaceutical supply chain digital governance at PSCG-ERM DGIM Level 4 requires explicit organisational culture alignment ensuring information security governance supports rather than constrains regulatory evidence management (Olatunde-Thorpe et al., 2021). Big data-enabled predictive models for anticipating infectious disease outbreaks at population and regional levels confirm that epidemiological demand signal monitoring in the PSCG-ERM's SCSG demand forecasting dimension can achieve predictive validity for medicine demand surge events (Oparah et al., 2022). Framework for designing national real-time disease surveillance dashboards for public health stakeholders confirms that national disease surveillance infrastructure directly informs pharmaceutical supply chain demand forecasting and shortage early warning systems in the PSCG- ERM's integrated SCSG and AEG governance architecture (Oparah et al., 2023a). Climate- sensitive transmission models for projecting disease dynamics under changing environmental conditions confirm that pharmaceutical supply chain demand governance in the PSCG-ERM's SCSG dimension requires integration of climate-sensitive disease burden projection models for accurate long-term inventory planning in African markets (Oparah et al., 2023b). A comprehensive AI governance risk index to support global enterprise decision-making confirms that AI-assisted composite governance risk scoring at the PSCG-ERM composite dimension level requires transparent methodology with documented scoring criteria and audit trail infrastructure (Anichukwueze, Osuji, and Oguntegbe, 2023). Framework for scaling mobile health solutions for chronic disease monitoring and treatment adherence improvement confirms that pharmaceutical IJHPR supply chain access governance requires integration with digital health solutions enabling adherence monitoring alongside medicine dispensing (Oparah et al., 2021). Predictive analytics framework for forecasting emergency room visits and optimizing healthcare resource allocation confirms that emergency healthcare demand forecasting is directly relevant to pharmaceutical supply chain demand surge management in the PSCG-ERM's SCSG demand governance specification (Ezeh et al., 2021). Digital twins for procurement and supply chains confirm that digital twin architecture with real-time monitoring, scenario simulation, and predictive cost avoidance provides the technical reference for the PSCG-ERM's SCSG dimension Level 4 integrated digital supply chain monitoring specification (Adesanya et al., 2020). Digital twin simulations applied to financial risk management confirm that digital twin simulation environments integrating real-time data and predictive algorithms achieve multi-domain risk governance quality substantially exceeding conventional static models, directly informing the PSCG-ERM's DGIM and ERM dimensions' digital monitoring specifications (Adesanya et al., 2022b). Intelligent customer engagement chatbots confirm that AI-driven patient and stakeholder engagement platforms integrating natural language processing and machine learning achieve 24/7 accessible service delivery with measurable improvements in user experience and compliance transparency, directly relevant to the PSCG-ERM's AEG dimension's digital access governance specification (Adesanya et al., 2023). Procurement cost efficiency for global SaaS portfolios confirms that systematic benchmarking governance achieves up to 27% greater cost efficiency than ad hoc procurement approaches, directly informing the PSCG-ERM's SCSG procurement governance Level 4 specification (Onyelucheya, Adesanya, Okafor, and Farounbi, 2023). Cyber threat actor analysis models confirm that systematic adversarial threat modelling improves proactive security planning in enterprise digital governance contexts directly relevant to the PSCG- ERM's DGIM cybersecurity governance specification (Dosunmu and Ogundele, 2023). AI-driven decision models supporting corporate finance strategy confirm that AI-assisted decision systems improve governance decision quality through machine learning, natural language processing, and multi-dimensional predictive analytics, directly informing the PSCG-ERM's DGIM Level 4 AI-assisted governance specification (Adesanya et al., 2022a). Human-in-the-loop machine learning confirms that embedding structured expert judgement into AI governance pipelines produces higher domain-specific performance in regulated contexts directly relevant to the PSCG-ERM's DGIM AI-assisted governance specification (Ladapo, Dosunmu, Jooda, and Abolaji, 2022a). Navigating digital transformation confirms that evidence-based digital migration planning with embedded security controls and transparent governance generates durable operational value in pharmaceutical digital governance contexts (Ladapo et al., 2022b). Security audit and enterprise risk assessment frameworks for resilient information systems confirm that integrated security auditing and enterprise risk assessment frameworks provide the governance architecture for the PSCG-ERM's DGIM dimension specification at Level 3 and above where pharmaceutical digital governance systems require formal security assurance (Dosunmu and Ogundele, 2019). Threat intelligence integration frameworks confirm that structured threat intelligence integration supports anticipatory security governance in pharmaceutical digital infrastructure environments where supply chain disruption signals and pharmacovigilance data require cybersecurity protection (Dosunmu and Ogundele, 2022). Incident response and digital forensics strategies confirm that integrated incident response and forensic readiness preserves regulatory data integrity under adverse cyber conditions, directly informing the PSCG-ERM's DGIM resilience specification (Dosunmu and Ogundele, 2021). IJHPR Reconciling chemical safety with circular-economy targets confirms that integrating REACH compliance, lifecycle greenhouse gas footprint assessment, and regulatory risk governance requires multi-criteria governance instruments and transparent supply-chain traceability analogous to the PSCG-ERM's ERM dimension specification for pharmaceutical manufacturing site chemical safety governance (Okojie and Abioye, 2020). This framework's four sequential decision gates for source qualification, hazard screening, lifecycle benchmarking, and regulatory horizon scanning directly inform the PSCG-ERM's ERM Level 4 and Level 5 specifications for integrated environmental compliance governance in pharmaceutical supply chains operating across multiple regulatory jurisdictions. Cross-border market entry under regulatory uncertainty confirms that integrated financial-legal-GTM decision frameworks generate superior regulatory market access outcomes in volatile cross-jurisdictional environments analogous to the PSCG-ERM's AEG access equity governance and multi-country implementation profile specifications (Adesanya et al., 2018). Finance-led process redesign and OPEX reduction confirms that finance-led operational redesign generates measurable cost savings in regulated supply chain environments, providing the methodological reference for the PSCG-ERM's SCSG Level 4 finance-aligned performance optimisation governance (Okafor et al., 2021). Estimating ROI of digital transformation confirms that pharmaceutical supply chain digital governance investment generates measurable financial returns through compliance efficiency improvement and operational expenditure reduction (Okafor et al., 2022). Industrial-scale transfer pricing operations confirms that cross-jurisdictional regulatory compliance governance at scale requires enterprise-grade automation and quality assurance directly informing the PSCG-ERM's RCG dimension specification for multi-country regulatory filing governance (Dako et al., 2021). Benchmarking enterprise software procurement prices confirms that systematic procurement benchmarking governance generates substantially higher cost efficiency than ad hoc approaches in pharmaceutical digital governance contexts (Farounbi et al., 2022). Blockchain microservices architectures for inclusive financial platforms confirm that blockchain-based governance infrastructure provides transparent, immutable audit trails for pharmaceutical supply chain compliance documentation at PSCG-ERM DGIM Level 4 and Level 5 (Adesanya et al., 2020c). Governance of related-party transactions confirms that structured control-design frameworks for compliance transparency and auditability in complex multi-party pharmaceutical supply chain governance directly inform the PSCG-ERM's RCG compliance documentation specification (Dako et al., 2019). Evidence on pharmaceutical research and development economics confirms that the median capitalised investment to bring a new drug to market was $985 million between 2009 and 2018, with the total cost rising substantially when the expense of failed trials is incorporated; these figures provide the economic baseline against which the PSCG-ERM's supply chain governance investment analysis and regulatory compliance governance cost modelling are anchored (Wouters, McKee, and Luyten, 2020). Research on supply chain transparency confirms that active pharmaceutical ingredient production concentration in a small number of countries creates systemic pharmaceutical supply chain fragility that is especially acute for low- and middle-income countries, and that increasing transparency from upstream active ingredient sources is necessary to improve medicine availability under both routine and emergency conditions (Ardal et al., 2021). Pharmaceutical supply chain predictive modeling research confirms that machine learning models trained on institutional purchasing and formulary data can generate early-warning shortage signals with sufficient lead time to enable proactive supply interventions, directly validating the PSCG-ERM's SCSG Level 4 specification for AI-assisted supply monitoring and the ERM specification for IJHPR demand-supply imbalance risk governance (Liu, Colmenares, Tak, Vest, Clark, Oertel, and Pappas, 2021). Research on best practices in African medicines regulatory harmonisation initiatives confirms that transparent work-sharing, peer-reviewed technical assessments, and sustained secretariat capacity are critical governance enablers for pharmaceutical supply chain regulatory quality assurance across regional economic community frameworks, directly informing the PSCG-ERM's RCG and AEG specifications for multi-country supply governance (Ndomondo- Sigonda, Azatyan, Doerr, Agaba, and Harper, 2023). Research on regulatory reliance frameworks confirms that systematic reliance on trusted regulatory authority assessments achieves substantially reduced compliance cycle times and improved decision quality compared to fully independent dossier assessment, providing the governance reference for the PSCG-ERM's RCG specification at Level 3 and above where multi-country supply chain compliance governance relies on reliance-based assessment workflows (Duran, Canas, Urtasun, Machado-Alba, and Gutierrez Paez, 2021). Evidence on dangling accelerated approvals confirms that inadequate post-approval confirmatory trial governance and insufficient withdrawal mechanisms create sustained exposure to uncertain benefit-risk profiles across the medicines supply chain, directly informing the PSCG- ERM's pharmacovigilance and post-market risk management specifications under both the SCSG and ERM dimensions (Beaver and Pazdur, 2021). Evidence synthesising regulatory and health technology assessment perspectives on surrogate endpoint standards confirms that both regulatory approval systems and supply chain governance frameworks must incorporate validated endpoint evidence quality requirements to ensure that medicines entering supply chains have demonstrated genuine clinical benefit rather than surrogate signal optimisation (Dawoud, Naci, Ciani, and Bujkiewicz, 2021). Comparative analysis of accelerated and conditional approval frameworks across major regulatory jurisdictions confirms that design differences in confirmatory trial requirements and post-approval withdrawal mechanisms generate systematic variation in the evidentiary quality of products entering global pharmaceutical supply chains, a risk dimension the PSCG-ERM's ERM specification must address at Level 4 and Level 5 (Mehta, de Claro, and Pazdur, 2022). Cross-jurisdictional oncology approval timing evidence confirms substantial median delays in European approval relative to FDA authorisation, underscoring the supply chain access equity implications of regulatory pathway timing differences that the PSCG-ERM's AEG dimension addresses (Lythgoe, Desai, Gyawali, Savage, Krell, Warner, and Khaki, 2022). Endpoint naming and validation reform evidence confirms that progression-free survival continues to be used as a primary regulatory endpoint without meeting the validation threshold required for robust benefit-risk assessment, creating a post-market pharmacovigilance obligation that the PSCG-ERM's ERM specification must govern at Level 4 (Gyawali, Tregear, and Booth, 2022). Audience segmentation and forecasting model research confirms that structured predictive frameworks applied to stakeholder communication generate measurably higher targeting accuracy and engagement efficiency, directly informing the PSCG-ERM's AEG stakeholder communication governance specification at Level 3 and above where pharmaceutical organisations must deploy data-driven segmentation intelligence for patient access equity outreach (Basnet, Oghenemaiga, and Anene, 2021). Resilient logistics framework research for humanitarian supply chains confirms that integrating predictive analytics, IoT-enabled monitoring, and localised distribution intelligence substantially improves emergency response supply chain performance, with measurable reductions in disruption duration and geographic access gaps that directly validate the PSCG-ERM's SCSG resilience specification at Level 4 and Level 5 (Anene and Clement, 2022). IJHPR Predictive analytics research applied to financial risk detection and fraud prevention in public systems confirms that machine learning frameworks achieve substantially higher governance risk detection accuracy than rule-based compliance systems, directly informing the PSCG-ERM's ERM financial risk governance specification and the RCG compliance assurance specification at Level 4 (Adelanwa, Basnet, and Anene, 2023a). Real-time analytics and monitoring research confirms that continuously updated dashboards integrating multi-source platform data provide substantially higher operational visibility than periodic reporting, providing the technical reference for the PSCG-ERM's DGIM Level 4 real-time digital monitoring specification (Basnet, Oghenemaiga, and Anene, 2023). Data-driven digital transformation research for lifecycle performance management confirms that structured transformation frameworks integrating analytics with lifecycle stage metrics generate substantially better outcome measurement than piecemeal digitisation, directly informing the PSCG-ERM's DGIM specification for pharmaceutical supply chain digital governance transformation (Adelanwa, Basnet, and Anene, 2023b). Evidence on the high cost of prescription drugs in the United States confirms that per capita prescription drug spending in the United States substantially exceeds that in all comparable countries, driven by brand-name drug price increases far beyond inflation, with the analysis identifying multiple structural regulatory and market mechanisms that sustain elevated pricing without commensurate clinical benefit gains; this evidence directly informs the IRRMM's economic value domain specification and the MSEWRS's financing architecture analysis for pharmaceutical regulatory governance investment (Kesselheim, Avorn, and Sarpatwari, 2016). A systematic review of trial-level meta-analyses measuring the strength of association between surrogate endpoints and overall survival in oncology confirms that most surrogate endpoints used in cancer medicine have low or modest correlation with overall survival, with 104 of 193 individual trial-level correlations classified as low correlation; this evidence directly informs the RBAA- DM's scientific rigor criterion specification requiring structured surrogate endpoint validation as a precondition for risk-adjusted accelerated approval recommendations (Haslam, Hey, Gill, and Prasad, 2019). Research on the association between progression-free survival and patients' quality of life in cancer clinical trials confirms that improved progression-free survival is not reliably associated with improved quality of life outcomes, with only a quarter of phase 3 cancer drug trials demonstrating improved patient quality of life; this finding reinforces the scientific rationale for the RBAA-DM's composite benefit-risk scoring architecture and its weighting of patient-relevant endpoints above surrogate signal optimisation (Hwang and Gyawali, 2019). Evidence on negative confirmatory trials of accelerated approval cancer drugs confirms that when post-approval trials fail to demonstrate clinical benefit, regulatory withdrawal of approvals is substantially delayed and treatment guidelines are not consistently updated in response to negative evidence, creating sustained exposure to uncertain benefit-risk profiles across the pharmaceutical supply chain; this governance failure analysis directly informs the RBAA-DM's post-approval commitment architecture and the PSCG-ERM's pharmacovigilance governance specification (Gyawali, Rome, and Kesselheim, 2021a). Evidence on the need for reforms to the FDA's accelerated approval pathway confirms that the mandate requiring post-approval confirmatory studies has been inconsistently enforced, with approval withdrawals occurring substantially later than clinically appropriate after confirmatory failures; this analysis directly informs the RBAA-DM's implementation fidelity specification and the ARCH-Model's PARIS Phase 3 continental regulatory pathway governance standards (Gyawali, Ross, and Kesselheim, 2021b). IJHPR 4. Theoretical Framework 4.1 Integrated Supply Chain Governance Theory The PSCG-ERM Framework is grounded in integrated supply chain governance theory, which holds that pharmaceutical supply chain performance is irreducibly a multi-dimensional organisational property requiring simultaneous governance attention across structural, regulatory, environmental, digital, and equity dimensions. This theoretical position distinguishes the PSCG- ERM from single-dimension frameworks that address supply chain risk management, regulatory compliance, or digital governance independently: the integrated theory predicts that governance improvements in any single dimension will be systematically undermined by persistent failures in other dimensions, because pharmaceutical supply chain performance depends on the weakest governance link across the five dimensions rather than on the strongest. The cross-domain evidence from industrial safety governance confirms this prediction: organizations that invest heavily in technical documentation and quality compliance while neglecting intelligence, environmental, and stakeholder governance systematically underperform relative to their technical investment because each neglected dimension creates independent performance constraints (Arumosoye and Obriki, 2021). 4.2 Emerging Economy Contextualisation The PSCG-ERM is specifically designed for emerging economy contexts rather than as a generic pharmaceutical supply chain governance framework, reflecting the evidence that governance failures in emerging economy pharmaceutical supply chains have structural characteristics , regulatory capacity heterogeneity, digital infrastructure gaps, environmental governance limitations, equity deficits in rural and low-income access , that are not adequately addressed by governance frameworks developed for high-income country contexts. The barriers to technological adoption among smallholder farmers in remote rural areas confirms that governance framework adoption in resource-constrained contexts requires differentiated support strategies rather than uniform implementation approaches (Michael and Ogunsola, 2022a). Gender inclusion and equity across agricultural value chains confirms that equity governance in complex systems requires explicit attention to marginalization dimensions (Michael and Ogunsola, 2022b). These agricultural development policy insights directly inform the PSCG-ERM's Access and Equity Governance dimension, whose design is grounded in the recognition that pharmaceutical supply chain equity requires governance instruments specifically calibrated to the marginalization patterns of each target context. 4.3 Environmental Sustainability Integration The PSCG-ERM integrates environmental risk management as a core governance dimension rather than an optional sustainability add-on, reflecting three convergent evidence streams. First, the lifecycle risk assessment evidence confirms that manufacturing site environmental compliance failures generate supply disruptions through regulatory enforcement actions, directly connecting ERM to supply availability outcomes (Fal2022). Second, the industrial safety governance evidence confirms that environmental governance maturity predicts overall operational governance quality, making ERM a leading indicator of broader supply chain governance performance (Arumosoye and Obriki, 2021). Third, the global health evidence confirms that pharmaceutical supply chain environmental performance has direct patient health consequences through pharmaceutical waste contamination of water supplies, antibiotic resistance generation through inadequately managed IJHPR pharmaceutical effluents, and the climate vulnerability of supply chains dependent on refrigeration and temperature-controlled transport in environments experiencing increasing extreme weather events (Fal2023). The integrated physicochemical treatment strategies for produced water in arid environments confirms that environmental governance in pharmaceutical supply chains in arid climate zones requires specifically adapted technical approaches (Fal2023). 5. Dimension 1: Supply Chain Structural Governance 5.1 Dimension Definition and Scope The Supply Chain Structural Governance dimension assesses the organizational infrastructure, process systems, and performance monitoring architecture that pharmaceutical supply chain participants deploy to ensure continuous supply availability of quality-assured essential medicines from manufacturer to patient. SCSG encompasses supplier qualification and concentration management, inventory coverage monitoring, logistics performance governance, demand forecasting accuracy, distribution network adequacy, and supply disruption response planning. The dimension reflects the foundational supply chain governance finding that supply availability is the precondition for all other pharmaceutical supply chain quality dimensions: a supply chain that delivers high-quality medicines inconsistently or to only a subset of the intended population fails in its essential function regardless of the quality of its individual transactions. 5.2 Five Maturity Level Specifications Level 1 Initial: Supply chain operations are reactive and undocumented. Inventory management relies on manual stocktaking without defined reorder points. Supplier qualification is informal and based on historical relationships rather than documented quality criteria. Supply disruptions are managed ad hoc without pre-positioned alternative supplier arrangements. Demand forecasting is absent, with procurement based on prior-period consumption without population need adjustment. Distribution networks are not monitored for coverage gaps. Level 2 Developing: Basic supply chain documentation exists, including supplier lists, procurement procedures, and distribution schedules. Inventory monitoring is conducted through periodic stocktaking at defined intervals, but automated alert systems are absent. Supplier qualification requirements are documented but inconsistently applied. Simple demand forecasting models apply historical consumption data without seasonal or disease burden adjustment. Level 3 Defined: Systematic supply chain governance processes are fully documented and consistently applied across all supply chain levels. Inventory management systems with defined reorder points and automated low-stock alerts are deployed at major distribution nodes. Supplier qualification programs extend qualifying assessment to first-tier suppliers for all critical medicines. Demand forecasting models incorporate epidemiological data, seasonal patterns, and healthcare utilization trends. Distribution network coverage assessments are conducted annually with documented gap-remediation plans. Level 4 Managed: Quantitative supply chain performance monitoring with defined metrics and dashboards tracks supplier concentration ratios, inventory coverage days, distribution reach percentages, and demand forecast accuracy monthly at national and sub-national levels. Predictive analytics identify emerging supply disruption risks before they materialise, enabling pre-emptive alternative supplier activation. Dual-sourcing requirements are enforced for all WHO essential medicines with global API concentration exceeding 50 percent. Level 5 Optimised: Continuous supply chain performance optimisation using advanced analytics, machine learning demand forecasting, and real-time inventory visibility across all supply chain levels from manufacturer to IJHPR last-mile distribution point. Proactive supply chain resilience investment including strategic reserve management, pre-qualified supplier network maintenance, and supply disruption scenario planning generates measurable supply availability improvements. The supply chain governance system is recognised as a model for peer organisations and contributes to national and regional supply chain governance standard development. The asset lifecycle management and inventory visibility framework confirms the integrated data architecture required for Level 4 and Level 5 SCSG (Okonkwo et al., 2023). The supply chain resilience framework confirms the multi-site supplier qualification standards at Level 3 and above (Ogunwole et al., 2021). Regulatory- compliant procurement framework confirms continuous compliance monitoring standards at Level 3 and above (Okonkwo et al., 2021b). 5.3 SCSG Assessment Indicators The SCSG dimension is assessed through twelve primary behavioral indicators spanning all five maturity levels: supplier geographic concentration ratio monitoring frequency and alert threshold definition; inventory coverage tracking system deployment and alert architecture; demand forecasting methodology and epidemiological data integration; distribution network coverage assessment regularity and gap-remediation documentation; alternative supplier qualification program scope and activation procedure documentation; supply disruption response protocol specification and testing frequency; cold chain performance monitoring system deployment; transportation and logistics performance tracking and exception management; pharmaceutical waste management governance documentation; last-mile distribution reach monitoring; strategic reserve level adequacy for priority essential medicines; and procurement cost efficiency governance demonstrating value-for-money outcomes. The inventory availability model from energy facilities provides the threshold calibration reference: inventory coverage below 45 days at national level is scored at Level 1-2, 45-90 days at Level 2-3, 90-180 days at Level 3-4, and above 180 days for strategic reserves at Level 4-5 (Okonkwo, Ogunwole, and Okeke, 2018a). The strategic procurement optimization framework confirms supplier qualification standards at each level (Okonkwo, Ogunwole, and Okeke, 2018b). Table 1. SCSG Dimension: Maturity Level Indicators and Scoring Anchors Maturity Level Supply Chain Structural Indicator Assessment Criterion Illustrative Organisation Profile Level 1 , Ad Hoc No structured supplier qualification; single- source dependency unmanaged; inventory monitoring absent No formal approved supplier list; no safety stock policy; no supply disruption tracking mechanism Health facility receiving essential medicines from single national distributor with no visibility into upstream supply chain fragility Level 2 , Developing Basic supplier qualification initiated; partial safety stock maintenance; reactive shortage reporting Approved supplier list established for at least 50% of essential medicines; manual shortage reporting to national authority National medicines regulatory authority beginning supplier qualification programme; shortage reports submitted ad hoc when disruptions become severe IJHPR Level 3 , Defined Documented procurement governance policy; diversified supplier base for priority medicines; formalised safety stock targets Dual-source policy for Category A essential medicines; 60-day minimum safety stock target maintained; monthly supply monitoring reports generated Ministry of Health with formalised procurement governance; at least two qualified suppliers for each essential medicine on national list Level 4 , Managed Analytics-driven demand forecasting; predictive supply risk scoring; integrated supplier performance dashboard AI-assisted demand forecasting with 85% accuracy for 26-week rolling horizon; supplier risk scoring integrated into procurement decisions; real-time inventory visibility National health supply chain agency using integrated supply chain management platform with predictive analytics and real-time warehouse management system Level 5 , Optimising Continuous supply chain improvement; regional integration; digital twin supply chain governance Bilateral supply pooling agreements with at least two neighbouring countries; digital twin supply simulation operational; carbon- aligned procurement policy Regional health supply chain platform with shared procurement, pooled strategic reserves, and real- time cross-border visibility across multiple national health systems SCSG Indicator Level 1-2 Score Level 3 Score Level 4-5 Score Inventory coverage monitoring Manual periodic; no alerts Automated alerts at major nodes Real-time visibility all levels Supplier concentration management No monitoring; informal suppliers Dual-source requirements for critical medicines Predictive concentration risk management Demand forecasting Prior-period consumption only Epidemiological data integration ML-assisted demand prediction IJHPR Distribution reach monitoring Not assessed Annual coverage assessment with gap plans Monthly sub-national monitoring Supply disruption response Ad hoc; no pre-positioned protocols Defined protocols; tested annually Predictive pre-emption; automatic activation Strategic reserve adequacy Below 45 days national coverage 90-180 days for essential medicines 180+ days; continuously monitored Cold chain performance Manual temperature logs Automated monitoring; exception alerts Real-time IoT monitoring all nodes 6. Dimension 2: Regulatory Compliance Governance 6.1 Dimension Definition and Scope The Regulatory Compliance Governance dimension assesses the quality assurance, pharmaceutical regulatory compliance, pharmacovigilance, post-market surveillance, and cross- jurisdictional harmonization governance of pharmaceutical supply chains in emerging economy contexts. RCG encompasses good manufacturing practice compliance monitoring across the supply chain, medicine registration adequacy, pharmacovigilance and adverse drug reaction reporting, post-market quality surveillance, medicine falsification and substandard product detection, and participation in regional harmonization frameworks. The dimension integrates the WHO regulatory system strengthening evidence confirming that regulatory compliance capability is the foundational determinant of pharmaceutical supply chain quality assurance performance (WHO, 2016; WHO, 2017), with the industrial governance evidence confirming that compliance maturity follows the same staged progression applicable to all organisational governance domains (Arumosoye and Obriki, 2021). 6.2 Five Maturity Level Specifications Level 1: National regulatory authority has limited GMP inspection capacity, an incomplete medicine register, minimal pharmacovigilance infrastructure, and no participation in regional harmonization programs. Level 2: Basic regulatory infrastructure with GMP inspection capacity for domestic manufacturers, functional medicine register, basic adverse drug reaction reporting, and initial AMRH or regional harmonization guideline adoption. Level 3: WHO Maturity Level 2-3 regulatory system with systematic GMP inspection programs, comprehensive medicine register with regular updates, functional national pharmacovigilance centre meeting WHO minimum standards, post-market quality surveillance program covering priority essential medicines, and active REC-level harmonization program participation. Level 4: WHO Maturity Level 3 regulatory system with quantitative performance monitoring, automated pharmacovigilance signal detection, comprehensive post-market surveillance, and REC joint assessment programme contribution. Level 5: WHO Maturity Level 3-4 with predictive IJHPR compliance monitoring, active regional reference authority status, continental pharmacovigilance network participation, and contribution to international regulatory standard development. ICH Q10 and ICH Q9 quality system standards (ICH, 2000; ICH, 2008) provide the technical reference for Level 3 to Level 5 RCG specifications. WHO GBT (WHO, 2019b; WHO, 2021b) provides the maturity level benchmarking reference. AMRH (2020), SADC (2014), and EAC (2017; 2022) provide the regional harmonization participation reference. 6.3 RCG Assessment Indicators Twelve primary RCG behavioral indicators: WHO Maturity Level assessment score; GMP inspection frequency and quality for domestic manufacturers; medicine register completeness and update frequency; adverse drug reaction reporting rate per million population; national pharmacovigilance centre operational status and reporting quality; post-market quality surveillance programme sampling scope and testing frequency; substandard and falsified medicine detection system deployment; regional harmonization programme active participation status; joint assessment procedure participation for essential medicines; environmental compliance monitoring integration with GMP inspection; pharmacovigilance data sharing with regional networks; and regulatory inspection response and remediation governance quality. 7. Dimension 3: Environmental Risk Management 7.1 Dimension Definition and Scope The Environmental Risk Management dimension addresses the environmental compliance monitoring, environmental incident response, pharmaceutical waste management, cold chain environmental impact governance, and climate vulnerability assessment dimensions of pharmaceutical supply chain governance. ERM recognizes that pharmaceutical supply chains in emerging economies generate significant environmental risks , through API synthesis solvent discharge, biological waste generation, pharmaceutical waste contamination of water supplies, cold chain refrigerant release, and packaging waste, whose management requires dedicated governance infrastructure that current pharmaceutical supply chain governance frameworks typically address inadequately or not at all. The lifecycle risk assessment framework for offshore produced water management provides the primary methodological reference: it demonstrates that environmental risk governance in industrial production contexts requires integrated monitoring of chemical, biological, operational, and regulatory compliance signals rather than managing each environmental risk category independently (Fal2022). The physicochemical and bio-based treatment strategies for produced water in arid environments confirms that ERM governance in resource-constrained emerging economy contexts requires adaptation of global technical frameworks to local conditions (Fal2023). 7.2 Environmental Standards Specification for Pharmaceutical Supply Chains The PSCG-ERM's environmental standards specification for pharmaceutical supply chains in emerging economies defines governance requirements across five environmental impact categories. Category 1, Pharmaceutical effluent management: API manufacturing sites must operate wastewater treatment systems achieving defined pharmaceutical active substance removal efficiencies, with quarterly sampling and testing against harmonized standards and annual reporting to national regulatory and environmental authorities. Category 2, Pharmaceutical solid waste: Manufacturing and distribution operations must classify and manage pharmaceutical waste IJHPR according to WHO and national pharmaceutical waste management guidelines, with segregation requirements for API-containing waste, cytotoxic products, biological medicines, and returned medicines at all supply chain levels. Category 3, Cold chain environmental impact: Cold chain operations must maintain refrigerant management records, conduct annual refrigerant leak inspections, and transition to low-global-warming-potential refrigerants on defined timelines where technically feasible. Category 4, Packaging sustainability: Pharmaceutical packaging governance must include post-market packaging waste quantification, secondary packaging minimization targets, and recycling program participation where national waste management infrastructure supports this. Category 5, Climate vulnerability assessment: National and facility- level pharmaceutical supply chain climate vulnerability assessments must identify supply chain nodes most vulnerable to extreme weather events, infrastructure disruption, and temperature exceedance with defined remediation investment plans. 7.3 ERM Maturity Level Specifications Level 1: Environmental governance absent or reactive; no pharmaceutical waste management documentation; no environmental monitoring at supply chain facilities; no climate vulnerability awareness. Level 2: Basic environmental documentation with pharmaceutical waste classification guidelines adopted but inconsistently implemented; periodic facility environmental inspections; awareness of cold chain environmental impact without active management. Level 3: Systematic environmental governance with annual pharmaceutical waste audits, wastewater treatment monitoring quarterly, refrigerant management records maintained, packaging waste quantification, and initial climate vulnerability assessment. Level 4: Quantitative environmental performance monitoring with monthly environmental metrics dashboards, automated wastewater treatment performance alerts, proactive refrigerant transition programme, packaging sustainability targets with annual performance tracking, and climate vulnerability remediation investment plans. Level 5: Predictive environmental management with AI-assisted environmental compliance monitoring, proactive regulatory engagement on environmental standard development, recognised environmental excellence within the pharmaceutical sector, and contribution to international pharmaceutical environmental governance standards. The lifecycle risk assessment framework confirms the integrated environmental monitoring infrastructure at Level 3 to Level 5 (Fal2022). The physicochemical treatment strategies framework confirms the technical approaches for Level 3 and above wastewater management (Fal2023). Safety governance maturity model confirms the staged environmental governance progression (Arumosoye and Obriki, 2021). 7.4 ERM Assessment Indicators Twelve primary ERM behavioral indicators: pharmaceutical wastewater treatment system deployment and performance monitoring frequency; pharmaceutical solid waste classification and disposal documentation; returned medicines governance and disposal management; cold chain refrigerant inventory and leak management records; packaging waste quantification and minimization program implementation; climate vulnerability assessment completion and remediation investment planning; environmental incident response protocol specification and testing; regulatory environmental compliance certificate maintenance; environmental audit programme scope and remediation timeline management; pharmaceutical supply chain carbon footprint monitoring; water use efficiency governance at manufacturing and distribution facilities; and participation in national or regional pharmaceutical environmental governance networks. IoT- IJHPR driven environmental monitoring model provides the technical reference for Level 4 and Level 5 ERM infrastructure (Odejobi, Hammed, and Ahmed, 2020). Table 2. ERM Dimension: Environmental Standards and Maturity Level Performance Requirements Environmental Standard Category Level 3 Minimum Requirement Level 4 Target Level 5 Best Practice Relevant Regulatory Reference GHG Emissions Governance Scope 1 and 2 emissions inventory completed; annual reporting initiated Science-based emissions reduction targets aligned to 1.5°C pathway; Scope 3 supplier emissions measured Net-zero supply chain roadmap; circular packaging and API recovery programme; biodiversity impact integration Paris Agreement; SBTI pharmaceutical sector guidance; EU Taxonomy Regulation (2020) Chemical Safety and Hazardous Waste Hazardous waste management plan compliant with national regulation; scheduled disposal records maintained Third-party hazardous waste audit completed annually; pharmaceutical effluent monitoring at manufacturing sites REACH-aligned chemical safety management across global supply chain; closed-loop API waste recovery systems EU REACH Regulation; Basel Convention; WHO pharmaceutical waste guidelines Water Stewardship Water consumption monitoring at all owned sites; regulatory discharge compliance confirmed Facility-level water recycling programme; pharmaceutical effluent treatment before discharge; water risk mapping completed Alliance for Water Stewardship certification at high-water-risk sites; community watershed protection commitments AWS Standard; WHO water quality guidelines; WBCSD water stewardship principles Environmental Impact Assessment Regulatory EIA completed for all new manufacturing capacity Proactive EIA for supply chain expansion including API supplier sites Continuous environmental impact monitoring with community engagement mechanisms and public reporting UNEP EIA principles; World Bank IFC Performance Standards; ISO 14001 IJHPR Circular Economy Integration Post-consumer medicine packaging take- back programme initiated Recyclable primary and secondary packaging adopted across 60% of product range Full lifecycle assessment completed; reusable container pilot for bulk API shipments; packaging design- for-disassembly policy EU Circular Economy Action Plan; Ellen MacArthur Foundation pharmaceutical sector frameworks Environmental Category Level 1-2 Minimum Level 3 Standard Level 4-5 Target Pharmaceutical effluent No treatment monitoring; no sampling Quarterly sampling; annual reporting to authority Monthly automated monitoring; real-time alerts Pharmaceutical waste No classification system WHO waste classification adopted; annual audit Automated waste tracking; zero unmanaged disposal Cold chain refrigerants No refrigerant records Annual leak inspection; records maintained Low-GWP transition programme; continuous monitoring Packaging sustainability No waste quantification Annual packaging waste quantification Minimization targets with annual performance review Climate vulnerability No assessment Initial vulnerability assessment complete Remediation investment plan implemented Environmental monitoring system No digital monitoring Periodic manual records Automated IoT-based continuous monitoring 8. Dimension 4: Digital Governance and Information Management 8.1 Dimension Definition and Scope The Digital Governance and Information Management dimension assesses the information technology infrastructure, data governance architecture, analytics capability, cybersecurity governance, and interoperability standards deployment that pharmaceutical supply chain IJHPR participants use to monitor performance, ensure data quality, enable evidence-based decision- making, and connect supply chain data systems across organisational and jurisdictional boundaries. DGIM encompasses electronic medicine registers and product authentication systems, demand information systems, pharmacovigilance data platforms, supply chain visibility platforms enabling real-time inventory and distribution monitoring, and the data governance frameworks governing cross-organisational and cross-jurisdictional data sharing. The dimension reflects the evidence that digital governance investment is the primary enabling capability for Level 4 and Level 5 performance in all other PSCG-ERM dimensions: supply chain structural governance requires digital inventory monitoring; regulatory compliance governance requires automated pharmacovigilance and post-market surveillance; environmental risk management requires IoT- based environmental monitoring; and access and equity governance requires digital health facility mapping and service utilization data. 8.2 Five Maturity Level Specifications Level 1: No dedicated pharmaceutical supply chain digital infrastructure; paper-based records; no electronic medicine register; no digital supply chain monitoring capability. Level 2: Basic electronic medicine register deployed; electronic adverse drug reaction reporting implemented; limited supply chain visibility using spreadsheet-based inventory tracking without real-time update capability. Level 3: Functional pharmaceutical supply chain digital platform with real-time inventory visibility at major distribution nodes, electronic product authentication for priority essential medicines, integrated pharmacovigilance database meeting WHO minimum electronic standards, and basic supply chain analytics capability. Level 4: Advanced digital supply chain governance with AI-assisted demand forecasting, automated quality alert systems, pharmacovigilance signal detection algorithms, environmental monitoring IoT integration, interoperable data architecture connecting national supply chain system with REC and WHO surveillance networks, and cybersecurity governance aligned with ISO 27001 or equivalent standards. Level 5: Predictive digital governance with machine learning across all supply chain performance dimensions, federated data architecture enabling cross-jurisdictional analytics without compromising national data sovereignty, real-time continental supply chain intelligence integration, and AI-assisted regulatory compliance monitoring across the full supply chain. 8.3 DGIM Assessment Indicators Twelve primary DGIM behavioral indicators: electronic medicine register deployment scope and update frequency; supply chain visibility platform deployment and real-time data coverage at national and sub-national levels; pharmacovigilance electronic reporting system coverage and data quality; product authentication system deployment for priority essential medicines; demand information system accuracy and healthcare utilization data integration; data governance framework documentation addressing data sovereignty, access control, and purpose limitation; cybersecurity governance documentation and incident response capability; environmental monitoring IoT system deployment at manufacturing and distribution facilities; AI-assisted analytics capability for supply chain performance prediction; data sharing agreements with regional pharmacovigilance and supply chain networks; patient-level supply chain data protection governance aligned with national data protection legislation; and analytics workforce capability supporting evidence-based supply chain decision-making. Legal and ethical risk modeling in enterprise data protection confirms the data governance framework architecture (Mbonu et al., IJHPR 2018). Comparative data protection regulations confirm cross-jurisdictional data governance standards (Mbonu et al., 2019). AI techniques for secure software testing confirm machine learning quality monitoring applicability (Mbonu et al., 2021a). Business intelligence dashboard frameworks confirm integrated performance monitoring deployability (Sanni and Atima, 2021). Data privacy governance for cross-border digital platforms confirms international data sharing architecture (Annan, 2022). 9. Dimension 5: Access and Equity Governance 9.1 Dimension Definition and Scope The Access and Equity Governance dimension assesses the governance infrastructure ensuring that essential medicines reach all population segments regardless of geographic location, income level, gender, or other characteristics associated with historical access inequality. AEG encompasses geographic access monitoring including rural and remote population coverage, affordability governance including price regulation and subsidy program management, gender equity in pharmaceutical access, health literacy and medicine information governance, and patient- centered accountability mechanisms ensuring that supply chain performance is evaluated against the access outcomes experienced by the populations the supply chain serves rather than solely against supply chain operational metrics. The dimension reflects the evidence that pharmaceutical supply chains in emerging economies systematically underserve populations facing multiple marginalisation dimensions simultaneously, and that correcting these systemic inequities requires dedicated governance attention rather than reliance on the general supply chain governance improvements generated by SCSG, RCG, ERM, and DGIM dimension improvements alone. 9.2 Five Maturity Level Specifications Level 1: Access governance absent; no systematic monitoring of geographic coverage, affordability, or equity outcomes; no specific governance provisions for vulnerable populations. Level 2: Basic geographic access data collected at national level; essential medicines price monitoring initiated; initial gender equity data disaggregation in health information systems. Level 3: Systematic access governance with annual geographic access assessments documenting coverage gaps at district level, essential medicines price monitoring and affordability assessment, gender-disaggregated access monitoring with defined equity targets, and formal community accountability mechanisms at health facility level. Level 4: Quantitative equity performance monitoring with sub-national access dashboards, price regulation enforcement with documented compliance rates, evidence-based equity target-setting with annual performance tracking, and formal patient and community engagement in supply chain governance. Level 5: Predictive equity governance identifying emerging access inequality patterns before they generate health disparities, AI-assisted geographic coverage optimization, supply chain equity outcomes integrated into national pharmaceutical policy performance accountability, and recognized contribution to global pharmaceutical access equity governance standards. Gender inclusion and equity frameworks from agricultural value chains confirm AEG Level 3 to Level 5 equity governance design principles (Michael and Ogunsola, 2022b). Healthcare workforce planning and governance framework confirms AEG's health system governance integration (Omaghomi, Akinlolu, and Fapohunda, 2023). Real-time health informatics confirms digital equity monitoring applicability (Nnaji and Akinlolu, 2022). IJHPR 9.3 AEG Assessment Indicators Twelve primary AEG behavioral indicators: geographic coverage assessment regularity and sub- national granularity; essential medicines price monitoring frequency and affordability assessment methodology; gender-disaggregated access monitoring system deployment and equity target- setting; rural and remote population service coverage percentage for priority essential medicines; patient and community accountability mechanism deployment at facility level; health literacy and medicine information governance documentation; medicine price regulation enforcement rate and compliance monitoring; supply chain equity outcome integration in national pharmaceutical policy performance frameworks; community feedback mechanism deployment and response governance; income-based access affordability assessment methodology; disability-adjusted access barrier documentation and remediation planning; and inter-sectoral governance coordination between pharmaceutical supply chain and social protection systems addressing access financing for low- income populations. Table 3. PSCG-ERM Five-Dimension Framework: Scope, Maturity Levels, and Primary Performance Indicators Dimension Weig ht Maturity Levels Primary Performance Indicators Assessment Method SCSG: Supply Chain Structural Governance 25% Level 1 (Ad Hoc) through Level 5 (Optimising) Supplier concentration index; safety stock coverage ; supply disruption frequency per year; procurement cycle time Structured self-assessment with documentary evidence review; external supply chain audit where applicable RCG: Regulatory Compliance Governance 25% Level 1 (Ad Hoc) through Level 5 (Optimising) GMP audit critical finding rate; PSUR submission compliance rate; marketing authorisation cycle time; pharmacovigilance signal detection lag Regulatory document review; national authority performance data; third- party GMP certification verification ERM: Environmental Risk Management 20% Level 1 (Ad Hoc) through Level 5 (Optimising) GHG emissions per unit produced; chemical waste volume; water intensity index; environmental audit frequency Site environmental audit; GHG emissions disclosure review; environmental management certification (ISO 14001) status DGIM: Digital Governance and 15% Level 1 (Ad Hoc) through Level 5 (Optimising) IT governance coverage; cybersecurity assessment frequency; data quality index; Systems review; IT governance framework documentation; third-party IJHPR Information Management digital platform integration score cybersecurity certification status AEG: Access and Equity Governance 15% Level 1 (Ad Hoc) through Level 5 (Optimising) Essential medicines availability rate (%); out-of-stock incidence (days/year); affordability index; geographic access coverage (%) National stockout data review; price monitoring survey; geographic coverage mapping; equity- adjusted access score Dimension Primary Scope Level 3 Key Requirement Level 5 Distinguishing Feature Primary Cross-Domain Evidence SCSG: Supply Chain Structural Supplier qualification; inventory; logistics; demand forecasting; disruption response Dual-source for critical medicines; 90-180 day national reserve; automated alerts Real-time visibility all levels; ML forecasting; predictive disruption prevention Supply chain resilience framework; inventory availability model RCG: Regulatory Compliance GMP compliance; medicine registration; pharmacovigilance; post-market surveillance; harmonization WHO ML 2-3; functional PV centre; post-market surveillance programme; REC participation WHO ML 3-4; reference authority status; continental PV network WHO GBT; ICH Q10; AMRH; EAC harmonization evidence ERM: Environmental Risk Pharmaceutical effluent; waste; cold chain; packaging; climate vulnerability Quarterly wastewater sampling; annual waste audit; refrigerant records; climate assessment AI-assisted environmental monitoring; low-GWP transition; climate remediation Lifecycle risk assessment framework; produced water treatment strategies DGIM: Digital Governance Electronic registers; supply chain visibility; PV platform; product authentication; analytics; cybersecurity Real-time visibility at major nodes; product authentication for priority medicines; integrated PV DB Federated cross-border analytics; ML prediction all dimensions; cybersecurity aligned with ISO 27001 Data protection governance models; IoT environmental monitoring; BI dashboards AEG: Access and Equity Geographic coverage; affordability; gender equity; patient accountability; rural access Annual district-level geographic access assessment; gender-disaggregated monitoring; community accountability IJHPR Predictive equity g